Echo IQ is trading at A$0.69, down 10.32%, with no clear company-specific catalyst identified.

  • No September 21, 2026 announcement was identified.
  • The latest material update, dated September 17, described an FDA appeal, Ombudsman review, and potential new 510(k) submission after an NSE determination involving clinical-validation statistics, not core technology.
  • Broader market indicators were largely unchanged, so the decline cannot be confidently attributed to global sentiment.